(AOF) – OSE Immunotherapeutics announces the issuance of a new patent in the United States relating to the use of the cancer vaccine Tedopi. The biotech specifies that the United States Patent and Trademark Office (USPTO) has issued a new patent protecting this therapeutic vaccine in the treatment of HLA-A2 positive patients with resistance secondary to treatment with an immune checkpoint inhibitor PD-1 /PD-L1. This new patent provides protection for the product in the United States until 2037.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.
2023-07-04 16:26:00
#OSE #Immunotherapeutics #patent #United #States #Tedopi #vaccine
